Magnesium compositions and uses thereof for neurological disorders
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-033/06
A61K-009/00
출원번호
US-0344417
(2016-11-04)
등록번호
US-9757414
(2017-09-12)
발명자
/ 주소
Liu, Guosong
Mao, Fei
출원인 / 주소
Neurocentria, Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
26
초록▼
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of application
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
대표청구항▼
1. A pharmaceutical composition comprising a pharmaceutically active agent and a pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient is magnesium threonate. 2. The pharmaceutical composition of claim 1, comprising about 10 mg to about 500 mg magnesium threonate.
1. A pharmaceutical composition comprising a pharmaceutically active agent and a pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient is magnesium threonate. 2. The pharmaceutical composition of claim 1, comprising about 10 mg to about 500 mg magnesium threonate. 3. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier or a second pharmaceutically acceptable excipient. 4. The pharmaceutical composition of claim 3, wherein the second pharmaceutically acceptable excipient is selected from the group consisting of a binder, filler, lubricant, dissolution aid, and any combination thereof. 5. The pharmaceutical composition of claim 3, wherein the second pharmaceutically acceptable excipient is selected from the group consisting of lactose, microcrystalline cellulose, silicon dioxide, titanium dioxide, stearic acid, starch, sodium starch glycolate, povidone, pregelatinized starch, croscarmellose, ethylcellulose, calcium phosphate, talc, sucrose, calcium stearate, hydroxy propyl methylcellulose, shellac, and any combination thereof. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated as an oral dosage form. 7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for oral administration, intranasal administration, or topical administration. 8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for transdermal administration or subdermal administration. 9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for intravenous administration. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for parenteral administration. 11. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for injection or for local infusion. 12. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for aerosol administration. 13. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for delivery to the brain via a pump or injection device. 14. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated in slow release or sustained release form. 15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated as a liquid, gel, semi-liquid, semi-solid, or solid. 16. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated as a tablet, capsule, powder, syrup, slurry, suspension, emulsion, or aerosol. 17. The pharmaceutical composition of claim 1, comprising at least 0.1 mg magnesium threonate. 18. The pharmaceutical composition of claim 1, comprising at least 1 mg magnesium threonate. 19. The pharmaceutical composition of claim 1, comprising at least 10 mg magnesium threonate. 20. The pharmaceutical composition of claim 1, comprising at least 300 mg magnesium threonate. 21. The pharmaceutical composition of claim 1, comprising about 10 mg to about 800 mg magnesium threonate. 22. The pharmaceutical composition of claim 1, comprising about 30 mg to about 1.5 g elemental magnesium. 23. The pharmaceutical composition of claim 1, comprising about 50 mg to about 800 mg elemental magnesium. 24. The pharmaceutical composition of claim 1, comprising elemental magnesium at a concentration of at least about 5 mg/L. 25. The pharmaceutical composition of claim 1, comprising elemental magnesium at a concentration of from about 5 mg/L to about 12 g/L. 26. A method of delivering magnesium to a subject in need thereof, comprising: administering the pharmaceutical composition of claim 1 to the subject, thereby effecting delivery of the magnesium threonate. 27. The method of claim 26, wherein the pharmaceutical composition is administered orally, intranasally, or topically. 28. The method of claim 26, wherein the pharmaceutical composition is administered transdermally or subdermally. 29. The method of claim 26, wherein the pharmaceutical composition is administered intravenously. 30. The method of claim 26, wherein the pharmaceutical composition is administered parenterally. 31. The method of claim 26, wherein the pharmaceutical composition is administered by injection or by local infusion. 32. The method of claim 26, wherein the pharmaceutical composition is administered by aerosol administration. 33. The method of claim 26, wherein the pharmaceutical composition is administered to the brain via a pump or injection device. 34. The method of claim 26, wherein the subject suffers from magnesium deficiency, mild cognitive impairment, Alzheimer's disease, Huntington's disease, autism, schizophrenia, cognitive decline, depression, dementia, attention deficit hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), Parkinson's disease, diabetes, cardiovascular disease, glaucoma, migraine, anxiety, mood disorder, or hypertension. 35. The method of claim 26, comprising providing about 1.5 mg/kg of body weight/day to about 18 mg/kg of body weight/day of elemental magnesium. 36. The method of claim 26, wherein the dosage form is administered for at least about 15 days. 37. The method of claim 26, wherein the dosage form is administered for at least about 1 month.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (26)
William T. Evans ; Dwight L. McKee, Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions.
George H. Clark ; Mary Ann Clark, Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet.
Yu Kai,CNX ; Wang Zhiwen,CNX ; Kou Fuping,CNX, L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof.
Skyler Jay S. (Key Biscayne FL) Frost Phillip (Miami Beach FL) Hahn Elliot F. (North Miami Beach FL), Method and composition for treatment of insulin resistance syndromes.
Glick J. Leslie (Potomac MD), Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory lo.
Atalla Rajai H. (Verona WI) Weinstock Ira A. (Madison WI) Hill Craig L. (Atlanta GA) Reiner Richard S. (Madison WI), Oxidation of lignin and polysaccharides mediated by polyoxometalate treatment of wood pulp.
Costa Jonathan L. (Wheaton IL) Diazgranados Jesus A. (Cali COX), Treatment of human diseases involving dysregulation or dysfunction of the nervous system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.